207 related articles for article (PubMed ID: 30230043)
1. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.
DiPippo AJ; Rausch CR; Kontoyiannis DP
Mycoses; 2019 Jan; 62(1):81-86. PubMed ID: 30230043
[TBL] [Abstract][Full Text] [Related]
2. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
[TBL] [Abstract][Full Text] [Related]
3. Real-world use-Isavuconazole at a large academic medical center.
Hassouna H; Athans V; Brizendine KD
Mycoses; 2019 Jun; 62(6):534-541. PubMed ID: 30851214
[TBL] [Abstract][Full Text] [Related]
4. Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy.
DiPippo AJ; Kontoyiannis DP
Clin Infect Dis; 2019 Oct; 69(9):1624-1627. PubMed ID: 30861066
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole salvage therapy: The Posifi study.
Fortun J; Gioia F; Cardozo C; Gudiol C; Diago E; José Castón J; Muñoz P; López J; Puerta-Alcalde P; Enzenhofer M; Ramos A; Frutos A; Machado M; Garcia-Vidal C; Parody R; Martín-Dávila P
Mycoses; 2019 Jun; 62(6):526-533. PubMed ID: 30864238
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
[TBL] [Abstract][Full Text] [Related]
7. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
Cumpston A; Caddell R; Shillingburg A; Lu X; Wen S; Hamadani M; Craig M; Kanate AS
Antimicrob Agents Chemother; 2015 Aug; 59(8):4424-8. PubMed ID: 25987632
[TBL] [Abstract][Full Text] [Related]
8. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
9. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.
Furfaro E; Signori A; Di Grazia C; Dominietto A; Raiola AM; Aquino S; Ghiggi C; Ghiso A; Ungaro R; Angelucci E; Viscoli C; Mikulska M
J Antimicrob Chemother; 2019 Aug; 74(8):2341-2346. PubMed ID: 31119272
[TBL] [Abstract][Full Text] [Related]
10. Isavuconazole for treatment of rare invasive fungal diseases.
Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Perfect JR; Oren I; Schmitt-Hoffmann AH; Giladi M; Marty FM; Rahav G
Mycoses; 2018 Aug; 61(8):518-533. PubMed ID: 29611246
[TBL] [Abstract][Full Text] [Related]
11. Isavuconazole shortens the QTc interval.
Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
[TBL] [Abstract][Full Text] [Related]
12. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation.
Pettit NN; Miceli MH; Rivera CG; Narayanan PP; Perissinotti AJ; Hsu M; Delacruz J; Gedrimaite Z; Han Z; Steinbeck J; Pisano J; Seo SK; Paskovaty A
J Antimicrob Chemother; 2017 Aug; 72(8):2355-2358. PubMed ID: 28475803
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).
Monforte A; Los-Arcos I; Martín-Gómez MT; Campany-Herrero D; Sacanell J; Berastegui C; Márquez-Algaba E; Sempere A; Nuvials X; Deu M; Castells L; Moreso F; Bravo C; Gavaldà J; Len O
Microbiol Spectr; 2022 Feb; 10(1):e0178421. PubMed ID: 35171022
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake.
Eiden C; Meniane JC; Peyrière H; Eymard-Duvernay S; Le Falher G; Ceballos P; Fegueux N; Cociglio M; Reynes J; Hillaire-Buys D
Eur J Clin Microbiol Infect Dis; 2012 Feb; 31(2):161-7. PubMed ID: 21611869
[TBL] [Abstract][Full Text] [Related]
15. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
Chitasombat MN; Kontoyiannis DP
Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
[TBL] [Abstract][Full Text] [Related]
16. Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time?
Perissinotti AJ; Marini BL
Mycoses; 2019 Mar; 62(3):214-216. PubMed ID: 30474309
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia.
Illmer T; Babatz J; Pursche S; Stölzel F; Schuler U; Schaich M; Ehninger G
Mycoses; 2011 Jul; 54(4):e143-7. PubMed ID: 20337942
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
20. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre.
Bowen CD; Tallman GB; Hakki M; Lewis Ⅱ JS
Mycoses; 2019 Aug; 62(8):665-672. PubMed ID: 31050373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
